Abstract
Most of the vaccines available today, albeit very effective, have been developed using traditional “old-style” methodologies. Technologies developed in recent years have opened up new perspectives in the field of vaccinology and novel strategies are now being used to design improved or new vaccines against infections for which preventive measures do not exist. The Reverse Vaccinology (RV) approach is one of the most powerful examples of biotechnology applied to the field of vaccinology for identifying new protein-based vaccines. RV combines the availability of genomic data, the analyzing capabilities of new bioinformatic tools, and the application of high throughput expression and purification systems combined with serological screening assays for a coordinated screening process of the entire genomic repertoire of bacterial, viral, or parasitic pathogens. The application of RV to Neisseria meningitidis serogroup B represents the first success of this novel approach. In this chapter, we describe how this revolutionary approach can be easily applied to any pathogen.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Keating GM, Noble S (2003) Recombinant hepatitis B vaccine (Engerix-B (R)) - A review of its immunogenicity and protective efficacy against hepatitis B. Drugs 63: 1021–1051.
Cutts FT, Franceschi S, Goldie S et al (2007) Human papillomavirus and HPV vaccines: a review. Bull World Health Org 85: 719–726.
Pizza M, Covacci A, Bartoloni A et al (1989) Mutants of pertussis toxin suitable for vaccine development. Science 246: 497–500.
Stephens DS (2007) Conquering the meningococcus. Fems Micro Rev 31: 3–14.
Riordan A (2010) The implications of vaccines for prevention of bacterial meningitis. Curr Opin Neurol 23: 319–324.
Pizza M, Scarlato V, Masignani V et al (2000) Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 287: 1816–1820.
Plotkin SA (2008) Correlates of vaccine-induced immunity. Clin Infect Dis 47: 401–409.
Medini D, Serruto D, Parkhill J et al (2008) Microbiology in the post-genomic era. Nature Rev Microbiol 6: 419–430.
Margarit I, Rinaudo CD, Galeotti CL et al (2009) Preventing bacterial infections with pilus-based vaccines: the Group B Streptococcus paradigm. J Infect Dis 199: 108–115.
Bagnoli F, Baudner B, Mishra R et al (2011) Designing the next generation of vaccines for global public health. OMICS: J Integrat Biol 17. [Epub ahead of print].
Scarselli M, Aricò B, Brunelli B et al (2011) Rational design of a meningococcal antigen inducing broad protective immunity. Sci Transl Med 3(91): 91–62.
Capecchi B, Adu-Bobie J, Di Marcello F et al (2005) Neisseria meningitidis NadA is a new invasin which promotes bacterial adhesion to and penetration into human epithelial cells. Mol Microbiol 55: 687–698.
Sambrook J, Russell DW (2001) Molecular cloning: a laboratory manual. CSHL Press
Coligan JE, Dunn BM, Ploegh HL et al (2002) Curr Prot Prot Sci 1: 6.0.1–6.0.4.
Scopes RK (1994) Protein purification: principles and practices. Springer, New York.
Hopkins TR (1991) Physical and chemical cell disruption for the recovery of intracellular proteins, in: Seetharam R, Sharma SK (Eds.), Purification and analysis of recombinant proteins, Marcel Dekker, New York, pp. 57–83.
Bornhorst JA, Falke JJ (2000) Purification of proteins using polyhistidine affinity tags. Methods Enzymol 326: 245–254.
Kneusel RE, Crowe J, Wulbeck M, Ribbe J (2000) Procedures for the analysis and purification of His-tagged proteins, in: Rapley R (Ed.), The Nucleic Acid Protocols Handbook, Springer, pp. 921–934.
Feavers I, Walker B (2010) Functional Antibody Assays. Meth Molec Biol 626: 199–211.
Giuliani MM, du-Bobie J, Comanducci M et al (2006) A universal vaccine for serogroup B meningococcus. Proc Nat Acad Sci USA 103: 10834–10839.
Qin L, Gilbert PB, Corey L et al (2007) A framework for assessing immunological correlates of protection in vaccine trials. J Infect Dis 196: 1304–1312.
Welsch JA, Moe GR, Rossi R et al (2003) Antibody to genome-derived neisserial antigen 2132, a Neisseria meningitidis candidate vaccine, confers protection against bacteremia in the absence of complement-mediated bactericidal activity. J Infect Dis 188: 1730–1740.
Tjalsma H, Bolhuis A, Jongbloed JDH et al (2000) Signal peptide-dependent protein transport in Bacillus subtilis: a genome-based survey of the secretome. Microbiol Mol Biol Rev 64: 515–547.
Tjalsma H, Antelmann H, Jongbloed JDH et al (2004) Proteomics of protein secretion by Bacillus subtilis: Separating the “secrets” of the secretome. Microbiol Mol Biol Rev 68: 207–233.
Acknowledgments
We are grateful to both Giorgio Corsi and Alessandro Aronica for artwork, Timothy Trevor Perkins and Jeannette Adu-Bobie for critical reading and manuscript editing, Enrico Luzzi and Francesca Ferlicca for their precious help in describing the ELISA and in vivo passive antibody protection methods and Beatrice Aricò, Maurizio Comanducci and Sara Comandi for their contribution.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Palumbo, E., Fiaschi, L., Brunelli, B., Marchi, S., Savino, S., Pizza, M. (2012). Antigen Identification Starting from the Genome: A “Reverse Vaccinology” Approach Applied to MenB. In: Christodoulides, M. (eds) Neisseria meningitidis. Methods in Molecular Biology, vol 799. Humana, Totowa, NJ. https://doi.org/10.1007/978-1-61779-346-2_21
Download citation
DOI: https://doi.org/10.1007/978-1-61779-346-2_21
Published:
Publisher Name: Humana, Totowa, NJ
Print ISBN: 978-1-61779-345-5
Online ISBN: 978-1-61779-346-2
eBook Packages: Springer Protocols